A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: Increasing glutamate uptake with PPARγ agonists

Journal of Clinical Neuroscience

Volumn 22, Issue 1, 2015, Pages 21-28

  Ching, Jared ^a,c   Amiridis, Stephanie ^a   Stylli, Stanley S ^a,b   Morokoff, Andrew P ^a,b   O'Brien, Terence J ^a   Kaye, Andrew H ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Glioma; Glutamate; PPAR gamma; Seizures

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; CEFTRIAXONE; CITAGLITAZONE; GLUTAMIC ACID; PENTETRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EXCITATORY AMINO ACID TRANSPORTER 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AMINO ACID TRANSPORT; ANTICONVULSANT ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN ISCHEMIA; CANCER STEM CELL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA ASSOCIATED SEIZURE; HUMAN; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BRAIN NEOPLASMS; COMPLICATION; METABOLISM; SEIZURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EXCITATORY AMINO ACID TRANSPORTER 2; GLIOBLASTOMA; GLUTAMIC ACID; HUMANS; PPAR GAMMA; SEIZURES;

EID: 84920676057     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.09.001     Document Type: Review

References (122)

1. J.A. Schwartzbaum, J.L. Fisher, and K.D. Aldape Epidemiology and molecular pathology of glioma Nat Clin Pract Neurol 2 2006 494 503
2. C. Adamson, O.O. Kanu, and A.I. Mehta Glioblastoma multiforme: a review of where we have been and where we are going Expert Opin Investig Drugs 18 2009 1061 1083
3. S.K. Singh, C. Hawkins, and I.D. Clarke Identification of human brain tumour initiating cells Nature 432 2004 396 401
4. M.S.M. van Breemen, R.M. Rijsman, and M.J.B. Taphoorn Efficacy of anti-epileptic drugs in patients with gliomas and seizures J Neurol 256 2009 1519 1526
5. S.C. Buckingham, S.L. Campbell, and B.R. Haas Glutamate release by primary brain tumors induces epileptic activity Nat Med 17 2011 1269 1274
6. T.I. Yuen, A.P. Morokoff, and A. Bjorksten Glutamate is associated with a higher risk of seizures in patients with gliomas Neurology 79 2012 883 889
7. R.P. Seal, and S.G. Amara Excitatory amino acid transporters: a family in flux Annu Rev Pharmacol Toxicol 39 1999 431 456
8. C.M. Anderson, and R.A. Swanson Astrocyte glutamate transport: review of properties, regulation, and physiological functions Glia 32 2000 1 14
9. A. Bernardo, and L. Minghetti Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists PPAR Res 2008 2008 864140
10. C. Romera, O. Hurtado, and J. Mallolas Ischemic preconditioning reveals that GLT1//EAAT2 glutamate transporter is a novel PPAR[gamma] target gene involved in neuroprotection J Cereb Blood Flow Metab 27 2007 1327 1338
11. J. Lee, and M. Reding Effects of thiazolidinediones on stroke recovery: a case-matched controlled study Neurochem Res 32 2007 635 638
12. S.A. Kliewer, S.S. Sundseth, and S.A. Jones Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-Activated receptors alpha and gamma Proc Natl Acad Sci USA 94 1997 4318 4323
13. L. Nagy, and J.W. Schwabe Mechanism of the nuclear receptor molecular switch Trends Biochem Sci 29 2004 317 324
14. M.E. Greene, B. Blumberg, and O.W. McBride Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping Gene Expr 4 1995 281 299
15. T. Sher, H.F. Yi, and O.W. McBride CDNA cloning, chromosomal mapping, and functional-characterization of the human peroxisome proliferator activated receptor Biochemistry 32 1993 5598 5604
16. T. Yoshikawa, Z. Brkanac, and B.R. Dupont Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2 Genomics 35 1996 637 638
17. M. Collino, N.S. Patel, and C. Thiemermann PPAR as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury Ther Adv Cardiovasc Dis 2 2008 179 197
18. L. Fajas, D. Auboeuf, and E. Raspe The organization, promoter analysis, and expression of the human PPAR gamma gene J Biol Chem 272 1997 18779 18789
19. R. Kumar, and E.B. Thompson The structure of the nuclear hormone receptors Steroids 64 1999 310 319
20. C.E. Juge-Aubry, E. Hammar, and C. Siegrist-Kaiser Regulation of the transcriptional activity of the peroxisome proliferator-Activated receptor alpha by phosphorylation of a dependent trans-Activating domain J Biol Chem 274 1999 10505 10510
21. G. Krey, O. Braissant, and F. L'Horset Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-Activated receptors by coactivator-dependent receptor ligand assay Mol Endocrinol 11 1997 779 791
22. E. Kalkhoven, J.E. Valentine, and D.M. Heery Isoforms of steroid receptor co-Activator 1 differ in their ability to potentiate transcription by the oestrogen receptor EMBO J 17 1998 232 243
23. S.A. Onate, S.Y. Tsai, and M.J. Tsai Sequence and characterization of a coactivator for the steroid-hormone receptor superfamily Science 270 1995 1354 1357
24. P. Dowell, J.E. Ishmael, and D. Avram P300 functions as a coactivator for the peroxisome proliferator-Activated receptor alpha J Biol Chem 272 1997 33435 33443
25. R.T Gampe Jr, V.G. Montana, and M.H. Lambert Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors Mol Cell 5 2000 545 555
26. W. Bourguet, V. Vivat, and J.M. Wurtz Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains Mol Cell 5 2000 289 298
27. B.M. Forman, P. Tontonoz, and J. Chen 15-deoxy-delta(12,14)-prostaglandin j(2) is a ligand for the adipocyte determination factor PPAR-gamma Cell 83 1995 803 812
28. Y. Yamamoto, H. Yamazaki, and T. Ikeda Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxic to HepG2 cells Drug Metab Dispos 30 2002 155 160
29. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
30. C. Patel, K.L. Wyne, and D.K. McGuire Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2 2005 61 66
31. H. Zhang, A. Zhang, and D.E. Kohan Collecting duct-specific deletion of peroxisome proliferator-Activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc Natl Acad Sci USA 102 2005 9406 9411
32. Y.F. Guan, C.M. Hao, and D.R. Cha Thiazolidinediones expand body fluid volume through PPAR gamma stimulation of ENaC-mediated renal salt absorption Nat Med 11 2005 861 866
33. A.M. Lincoff, K. Wolski, and S.J. Nicholls Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - a meta-Analysis of randomized trials JAMA 298 2007 1180 1188
34. J.D. Lewis, A. Ferrara, and T. Peng Risk of bladder cancer among diabetic patients treated with pioglitazone Interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
35. I.N. Colmers, S.L. Bowker, and S.R. Majumdar Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-Analysis Can Med Assoc J 184 2012 E675 E683
36. O. Braissant, and W. Wahli Differential expression of peroxisome proliferator-Activated receptor-Alpha, -beta, and -gamma during rat embryonic development Endocrinology 139 1998 2748 2754
37. S. Moreno, S. Farioli-Vecchioli, and M.P. Ceru Immunolocalization of peroxisome proliferator-Activated receptors and retinoid X receptors in the adult rat CNS Neuroscience 123 2004 131 145
38. J.W. Woods, M. Tanen, and D.J. Figueroa Localization of PPAR delta in murine central nervous system: expression in oligodendrocytes and neurons Brain Res 975 2003 10 21
39. L. Cristiano, A. Bernardo, and M.P. Ceru Peroxisome proliferator-Activated receptors (PPAR) and peroxisomes in rat cortical and cerebellar astrocytes J Neurocytol 30 2001 671 683
40. T.E. Cullingford, K. Bhakoo, and S. Peuchen Distribution of mRNAs encoding the peroxisome proliferator-Activated receptor alpha, beta and gamma and the retinoid X receptor alpha, beta and gamma rat central nervous system J Neurochem 70 1998 1366 1375
41. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
42. M. Abdelrahman, A. Sivarajah, and C. Thiemermann Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock Cardiovasc Res 65 2005 772 781
43. T. Sato, H. Hanyu, and K. Hirao Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease Neurobiol Aging 32 2011 1626 1633
44. G. Landreth Therapeutic use of agonists of the nuclear receptor PPAR gamma in Alzheimer's disease Curr Alzheimer Res 4 2007 159 164
45. M.K. Racke, A.R. Gocke, and M. Muir Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis J Nutr 136 2006 700 703
46. R.K. Chaturvedi, and M.F. Beal PPAR: a therapeutic target in Parkinson's disease J Neurochem 106 2008 506 518
47. T.L. Yue Tl, J. Chen, and W. Bao In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-Activated receptor-gamma agonist rosiglitazone Circulation 104 2001 2588 2594
48. K. Subbaramaiah, D.T. Lin, and J.C. Hart Peroxisome proliferator-Activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2 - evidence for involvement of activator protein-1 and CREB-binding protein/p300 J Biol Chem 276 2001 12440 12448
49. M.T. Heneka, D.L. Feinstein, and E. Galea Peroxisome proliferator-Activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase J Neuroimmunol 100 1999 156 168
50. T. Shimazu, I. Inoue, and N. Araki A peroxisome proliferator-Activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia Stroke 36 2005 353 359
51. S. Sundararajan, J.L. Gamboa, and N.A. Victor Peroxisome proliferator-Activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia Neuroscience 130 2005 685 696
52. M. Allahtavakoli, A. Shabanzadeh, and A. Roohbakhsh Combination therapy of rosiglitazone, a peroxisome proliferator-Activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats Basic Clin Pharmacol Toxicol 101 2007 309 314
53. F.C. Barone, and G.Z. Feuerstein Inflammatory mediators and stroke: new opportunities for novel therapeutics J Cereb Blood Flow Metab 19 1999 819 834
54. N.A. Victor, E.W. Wanderi, and J. Gamboa Altered PPAR gamma expression and activation after transient focal ischemia in rats Eur J Neurosci 24 2006 1653 1663
55. Y. Zhao, A. Patzer, and P. Gohlke The intracerebral application of the PPAR gamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain Eur J Neurosci 22 2005 278 282
56. Z. Ou, X. Zhao, and L.A. Labiche Neuronal expression of peroxisome proliferator-Activated receptor-gamma (PPAR gamma) and 15d-prostaglandin J(2) - mediated protection of brain after experimental cerebral ischemia in rat Brain Res 1096 2006 196 203
57. D.R. Curtis, and G.A. Johnston Amino acid transmitters in the mammalian central nervous system Ergeb Physiol Biol Chem Exp Pharmakol 69 1974 97 188
58. N.C. Danbolt Glutamate uptake Prog Neurobiol 65 2001 1 105
59. R. Sattler, and M. Tymianski Molecular mechanisms of calcium-dependent excitotoxicity J Mol Med (Berl) 78 2000 3 13
60. K.P. Doyle, R.P. Simon, and M.P. Stenzel-Poore Mechanisms of ischemic brain damage Neuropharmacology 55 2008 310 318
61. C. Culmsee, C.L. Zhu, and S. Landshamer Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia J Neurosci 25 2005 10262 10272
62. B.R. Broughton, D.C. Reutens, and C.G. Sobey Apoptotic mechanisms after cerebral ischemia Stroke 40 2009 E331 E339
63. S. Love Apoptosis and brain ischaemia Prog Neuropsychopharmacol Biol Psychiatry 27 2003 267 282
64. A.F. Samdani, T.M. Dawson, and V.L. Dawson Nitric oxide synthase in models of focal ischemia Stroke 28 1997 1283 1288
65. M.J. Sheardown, E.O. Nielsen, and A.J. Hansen 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline - a neuroprotectant for cerebral ischemia Science 247 1990 571 574
66. H. Shen, G.J. Chen, and B.K. Harvey Inosine reduces ischemic brain injury in rats Stroke 36 2005 654 659
67. C. Villmann, and C.M. Becker On the hypes and falls in neuroprotection: targeting the NMDA receptor Neuroscientist 13 2007 594 615
68. B.K. Harvey, M. Airavaara, and J. Hinzman Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke PLos One 6 2011 e22135
69. K. Chu, S.T. Lee, and K.H. Jung Upregulation of glutamate transporter-1 by ceftriaxone induces prolonged ischemic tolerance Stroke 38 2007 177 182
70. K. Chu, S.-T. Lee, and D.-I. Sinn Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation Stroke 38 2007 177 182
71. R. Verma, V. Mishra, and D. Sasmal Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury Eur J Pharmacol 638 2010 65 71
72. R. Sattler, B. Tyler, and B. Hoover Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma J Neurosurg 119 2013 878 886
73. A. Cimini, L. Cristiano, and A. Bernardo Presence and inducibility of peroxisomes in a human glioblastoma cell line Biochim Biophys Acta 1474 2000 397 409
74. E. Elstner, E.A. Williamson, and C. Zang Novel therapeutic approach: ligands for PPAR gamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells Breast Cancer Res Treat 74 2002 155 165
75. P. Sarraf, E. Mueller, and D. Jones Differentiation and reversal of malignant changes in colon cancer through PPAR gamma Nat Med 4 1998 1046 1052
76. M.W. Lee, D.S. Kim, and H.R. Kim Cell death is induced by ciglitazone, a peroxisome proliferator-Activated receptor gamma (PPAR gamma) agonist, independently of PPAR gamma in human glioma cells Biochem Biophys Res Commun 417 2012 552 557
77. C. Grommes, G.E. Landreth, and M.T. Heneka Antineoplastic effects of peroxisome proliferator-Activated receptor gamma agonists Lancet Oncol 5 2004 419 429
78. L. Tatenhorst, E. Hahnen, and M.T. Heneka Peroxisome proliferator-Activated receptors (PPAR) as potential inducers of antineoplastic effects in CNS tumors PPAR Res 2008 2008 204514 1-8
79. P. Wang, J. Yu, and Q. Yin Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway Neurochem Res 37 2012 2076 2084
80. Z. Wan, W. Shi, and B. Shao Peroxisome proliferator-Activated receptor gamma agonist pioglitazone inhibits beta-catenin-mediated glioma cell growth and invasion Mol Cell Biochem 349 2011 1 10
81. N. Embi, D.B. Rylatt, and P. Cohen Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase Eur J Biochem 107 1980 519 527
82. K. Leroy, and J.-P. Brion Developmental expression and localization of glycogen synthase kinase-3 beta in rat brain J Chem Neuroanat 16 1999 279 293
83. S. Kelly, H. Zhao, and G.H. Sun Glycogen synthase kinase 3 beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia Exp Neurol 188 2004 378 386
84. A. Martinez, M. Alonso, and A. Castro First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs from the treatment of Alzheimer's disease J Med Chem 45 2002 1292 1299
85. Z. Wang, K.S. Smith, and M. Murphy Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy Nature 455 2008 1205 1209
86. J. Tan, L. Zhuang, and H.S. Leong Pharmacologic modulation of glycogen synthase kinase-3β promotes p53-dependent apoptosis through a direct bax-mediated mitochondrial pathway in colorectal Cancer Cells 65 2005 9012 9020
87. S. Korur, R.M. Huber, and B. Sivasankaran GSK3beta regulates differentiation and growth arrest in glioblastoma Plos One 4 2009 e7443
88. R.J. Atkins, J. Dimou, and L. Paradiso Regulation of glycogen synthase kinase-3 beta (GSK-3b) by the Akt pathway in gliomas J Clin Neurosci 19 2012 1558 1563
89. M. Lo, Y.Z. Wang, and P.W. Gout The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases J Cell Physiol 215 2008 593 602
90. Z.C. Ye, and H. Sontheimer Glioma cells release excitotoxic concentrations of glutamate Cancer Res 59 1999 4383 4391
91. W.J. Chung, S.A. Lyons, and G.M. Nelson Inhibition of cystine uptake disrupts the growth of primary brain tumors J Neurosci 25 2005 7101 7110
92. S.A. Lyons, W.J. Chung, and A.K. Weaver Autocrine glutamate signaling promotes glioma cell invasion Cancer Res 67 2007 9463 9471
93. J. Chung, and H. Sontheimer Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-κB J Neurochem 110 2009 182 193
94. P.A. Robe, D.H. Martin, and M.T. Nguyen-Khac Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults BMC Cancer 9:372 2009 1 8
95. Z.C. Ye, J.D. Rothstein, and H. Sontheimer Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange J Neurosci 19 1999 10767 10777
96. J.F. de Groot, T.J. Liu, and W.K. Fuller The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo Cancer Res 65 2005 1934 1940
97. E. Pestereva, S. Kanakasabai, and J.J. Bright PPAR gamma agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells Br J Cancer 106 2012 1702 1712
98. W. Chearwae, and J.J. Bright PPAR gamma agonists inhibit growth and expansion of CD133+brain tumour stem cells Br J Cancer 99 2008 2044 2053
99. K.M. Kurian The impact of neural stem cell biology on CNS carcinogenesis and tumor types Pathol Res Int 2011 2011 685271
100. D.N. Louis Molecular pathology of malignant gliomas Annu Rev Pathol 1 2006 97 117
101. C. Stiles, and D.H. Rowitch Glioma stem cells: a midterm exam Neuron 58 2008 832 846
102. J.A. Gilley, and S.G. Kernie Excitatory amino acid transporter 2 and excitatory amino acid transporter 1 negatively regulate calcium-dependent proliferation of hippocampal neural progenitor cells and are persistently upregulated after injury Eur J Neurosci 34 2011 1712 1723
103. K. Okada, U. Yamashita, and S. Tsuji Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice Brain Res 1102 2006 175 178
104. R. Adabi Mohazab, M. Javadi-Paydar, and B. Delfan Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice Epilepsy Res 101 2012 28 35
105. H. Shafaroodi, L. Moezi, and H. Ghorbani Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide Brain Res Bull 87 2012 544 550
106. J.H. Choi, A.S. Banks, and J.L. Estall Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5 Nature 466 2010 451 457
107. J.H. Choi, A.S. Banks, and T.M. Kamenecha Antidiabetic actions of a non-Agonist PPAR gamma ligand blocking Cdk5-mediated phosphorylation Nature 477 2011 477 481
108. M. Ahmadian, J.M. Suh, and N. Hah PPAR gamma signaling and metabolism: the good, the bad and the future Nat Med 19 2013 557 566
109. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
110. C.K. Colton, Q. Kong, and L. Lai Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening J Biomol Screen 15 2010 653 662
111. R.D. Hawkins, G.C. Hon, and B. Ren Next-generation genomics: an integrative approach Nat Rev Genet 11 2010 476 486
112. M.I. Lefterova, D.J. Steger, and D. Zhuo Cell-specific determinants of peroxisome proliferator-Activated receptor gamma function in adipocytes and macrophages Mol Cell Biol 2010 2078 2089
113. M.S. Hamza, S. Pott, and V.B. Vega De-novo identification of PPARc/RXR binding sites and direct targets during adipogenesis PLoS One 4 2009 e4907
114. R.E. Kast, J.A. Boockvar, and A. Bruning A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care Oncotarget 4 2013 502 530
115. C. Grommes, J.C. Karlo, and C. Andrew The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model Cancer Chemother Pharmacol 71 2013 929 936
116. W.B. Chearwae, and J.J. Bright PPAR gamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells Br J Cancer 99 2008 2044 2053
117. R. Coras, A. Holsken, and S. Seufert The peroxisome proliferator-Activated receptor-γ agonist troglitazone inhibits transforming growth factor- β-mediated glioma cell migration and brain invasion Mol Cancer Therap 6 2007 1745 1754
118. A. Spagnolo, R.P. Glick, and H. Lin Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-Activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts J Neurosurg 106 2007 299 305
119. C. Grommes, G.E. Landreth, and M. Sastre Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-Activated receptor gamma agonist treatment Mol Pharmacol 70 2006 1524 1533
120. C. Grommes, G.E. Landreth, and U. Schlegel The nonthiazolidinedione tyrosine-based peroxisome proliferator-Activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells J Pharmacol Exp Ther 313 2005 806 813
121. D.C. Liu, C.B. Zang, and H.Y. Liu A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells Acta Pharmacol Sin 25 2004 1312 1319
122. V. Chandra, P. Huang, and Y. Hamuro Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA Nature 456 2008 350 356